When diagnosed with ovarian cancer in its most curable stage, Liz Stegall knew someone was watching over her — her dear friend, Linda.
Two new findings are adding to the understanding of ovarian cancer. One takes an important step by identifying a target that inhibits cell division. The other identifies a protein that unexpectedly regulates the creation of new blood vessels that feed a tumor from outside.
Researchers in one study found that depleting Salt Inducible Kinase 2, known as SIK2, from ovarian cancers made the cancer cells sensitive to paclitaxel, a commonly prescribed chemotherapeutic agent that inhibits cell division, making the drug more effective in stopping the cancer’s growth.
“通过改变癌细胞对毒品的敏感性来提高现有化学疗法的有效性的大型机会窗口，”MD.，MD.，MD.，MD.，MD.，MD.，MD。188bet体育网址“我们在寻找负责这种敏感性的蛋白质中，我们发现细胞分裂需要Sik2，其抑制性提供了一种改善卵巢癌化疗的新方法，这些方法应该进一步研究。”
Anil Sood，M.D.
在第二次研究中，与癌症进展相关的蛋白质 - 当它丰富的肿瘤内部时，发现还可以调节从外部饲喂肿瘤的新血管的产生。通过使用基于纳米粒子的基因沉默系统阻断蛋白质的产生，研究人员抑制了对肿瘤的新血管的形成，并导致卵巢癌小鼠模型中的肿瘤负担急剧降低。188bet体育网址
“我们发现，EZH2通过关闭阻止新血管形成的基因来促进肿瘤生长，”学习高级作家Anil Sood，M.D.，妇科肿瘤科学和癌症生物学部门教授。“用目前的抗血管生成药物治疗的肿瘤最终进展。该研究提出了开放新型治疗方法的开放门的血管生成（血管形成）的新机制。“
EZH2 has been associated with the progression and spread of bladder, breast, prostate and gastric cancers, as well as one type of pharynx cancer.
这两项研究都在2010年8月癌细胞中报告。
更多Stories From Conquest
